期刊文献+

131I治疗分化型甲状腺癌术后患者疗效影响因素研究 被引量:44

Influential factors on the effectiveness of 131I treatment on post-surgical differentiated thyroid cancer patients
原文传递
导出
摘要 目的 探讨影响分化型甲状腺癌(DTC)患者术后首次131I清除残留甲状腺组织(简称清甲)疗效和多次131I治疗转移灶(清灶)疗效的因素。方法回顾性分析首次接受大剂量清甲治疗的患者46例(分为成功组与未成功组)资料、多次清灶治疗的患者40例(分为临床缓解组和未缓解组)资料,对数据进行t检验、t’检验、X^2检验或Fisher确切概率法筛选影响因素,并做Logistic回归分析。结果用单因素分析筛选出手术方式、残余甲状腺质量、促甲状腺激素(TSH)水平、手术至清甲治疗时间和存在转移灶是影响清甲效果的因素(X2=5.804、t’=-5.258、t=7.376、X^2=8.867、X2=8.615,P均〈0.05)。Logistic回归分析得到的清甲成功的拟合方程为Y=3.766—0.947x,(残余甲状腺质量)-3.149x:(淋巴结转移)-3.373x,(远处转移)。对临床缓解率行单因素分析显示:甲状腺乳头状癌显著高于甲状腺滤泡状癌,仅有淋巴转移灶显著高于有远处转移灶,甲状腺全切显著高于其他手术方式(Fisher确切概率法,X。=7.278,P〈0.05);首次131I治疗前,临床缓解组的TSH水平明显高于未缓解组,甲状腺球蛋白(Tg)水平明显低于未缓解组(t=4.489、t=-4.906,P均〈0.01)。Logistic回归分析得到清灶成功拟合方程为:Y=-0.363+0.065x4(TSH水平)-0.250x5(Tg水平)。结论DTC患者首次清甲疗效的影响因素有手术方式、残余甲状腺质量、TSH、手术至清甲治疗时间和有无转移灶;其中残留甲状腺组织少、无淋巴结转移和无远处转移是提高成功率的关键因素。DTC患者清灶疗效的影响因素包括病理类型、手术方式、转移灶的部位、TSH和Tg;其中首次131I治疗前有较高水平的TSH和较低水平的强是提搞缓解率的关键因素。 Objective To investigate the influential factors on the effectiveness of the first 131I ablation therapy on thyroid remnant and of 131I treatment on metastatic lesions in differentiated thyroid cancer (DTC) patients. Methods Retrospectively,46 DTC cases (divided into complete-ablation group and incomplete-ablation group) of first 131I ablation were enrolled, and 40 DTC cases (divided into remission group and in-remission group) of consecutive 131I treatments on metastatic lesions were enrolled. Influential factors were analyzed (t-test, t'-test, x2-test, Fisher exact test) and logistic regression analysis was performed. Results For the first 131I ablation effectiveness, surgical method, remnant thyroid weight, thyroid stimulating hormone (TSH) level, interval between surgery and 131I ablation therapy, metastatic status were selected as influential factors (X2 = 5. 804, t' = - 5. 258, t' = 7. 376, X2 = 8. 867, X2 = 8. 615, all P 〈 0. 05 ). After logistic regression analysis, formula was obtained as y = 3. 766 - 0. 947x1( remnant thyroid weight) -3. 149 x2 (lymph node metastasis) -3. 373 x3 (distant metastasis). For metastatic treatment effectiveness, remission rate of papillary DTC was higher than that of follicular DTC, remission rate of patients with lymph node metastasis was higher than that of distant metastasis, remission rate of total thyroidectomy was higher than that of other types of thyroidectomy ( Fisher exact test, X2 = 7. 278, P 〈 0.05 ). In remission group, serum TSH level was much higher and thyroglobulin (Tg) level was much lower before the first ablation therapy ( t = 4. 489, t' = - 4. 906, all P 〈 0.01 ). After logistic regression analysis, formula was obtained as y = - 0. 363 + 0. 065 x4 ( TSH level) - 0.250 x5 ( Tg level). Conclusions Influential factors of success rate of the first 131I ablation therapy included surgical method, remnant thyroid weight, TSH level, interval between surgery and 131I ablation therapy and metastatic status, while determinant factors were thyroid remnant weight, lymph node metastatic status and distant metastatic status. The influential factors of success rate of 131I treatment on metastatic lesions included pathological type, surgical method, metastatic status, TSH level and Tg level, while determinant factors were TSH level and Tg level before the first 131I ablation therapy.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2010年第4期259-263,共5页 Chinese Journal of Nuclear Medicine
基金 国家自然科学基金(30900376) 天津市应用基础及前沿技术研究计划(10JCZDJC19000) 天津医科大学科学基金(2008KY20)
关键词 甲状腺肿瘤 外科手术 碘放射性同位素 治疗结果 Thyroid neoplasms Surgery, operation Iodine radioisotopes Treatment outcome
  • 相关文献

参考文献12

  • 1Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States,1973-2002.J Am Med Assoc,2006,295:2164-2167.
  • 2Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16:109-142.
  • 3Lundgren CI,Hall P,Dickman PW,et al.Clinically significant prognostic factors for differentiated thyroid carcinoma:a populationbased,nested case-control study.Cancer,2006,106:524-531.
  • 4Jukkola A,Bloigu R,Ebeling T,et al.Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications.Endocr Relat Cancer,2004,11:571-579.
  • 5傅宏亮,王辉,吴靖川,李佳宁,邹仁健,杜学亮.影响分化型甲状腺癌术后^131I清甲治疗疗效的因素分析[J].中华核医学杂志,2009,29(3):149-152. 被引量:34
  • 6Bilimoria KY,Bentrem DJ,Ko CY,et al.Extent of surgery affects survival for papillary thyroid cancer.Ann Surg,2007,246:375-381.
  • 7Do MY,Rhee Y,Kim DJ,et al.Clinical features of bone metastases resulting from thyroid cancer:a review of 28 patients over a 20-year period.Endocr J,2005,52:701-707.
  • 8Kumar A,Bal CS.Differentiated thyroid cancer.Indian J Pediatr,2003,70:707-713.
  • 9Mazzaferri EL,Robbins RJ,Spencer CA,et al.A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.J Clin Endocrinol Metab,2003,88:1433-1441.
  • 10Kim TY,Kim WB,Kim ES,et al.Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.J Clin Endocrinol Metab,2005,90:1440-1445.

二级参考文献16

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006.CA Cancer J Clin,2006,56:106-130.
  • 2Sawka AM,Thephamongkhol K,Brouwers M,et al.A systematic review and Meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab,2004,89:3668-3676.
  • 3Hackshaw A,Harmer C,Mallick U,et al.131Ⅰ activity for remnant ablation in patients with differentied thyroid cancer:a systematic review.J Clin Endocrinol Metab,2007,92:28-38.
  • 4Pacini F,Molinaro E,Castagna MG,et al.Ablation of thyroid residues with 30 mCi 131^I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.J Clin Endocrinol Metab,2002,87:4063-4068.
  • 5Doi SAR,Woodhouse NJ,Thalib L,et al.Ablation of the thyroid remnant and 131^I dose in differentiated thyroid cancer:a Meta-analysis revisited.Clin Med Res,2007,5:87-90.
  • 6Toubeau M,Touzery C,Arveux P,et al.Predictive value for disease progression of serum thyrogiohulin levels measured in the postoperative period and after 131^I ablation therapy in patients with differentiated thyroid cancer.J Nucl Med,2004,45:988-994.
  • 7Bemier MO,Morel O,Bodien P,et al.Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.Eur J Nucl Med Mol Imaging,2005,32:1418-1421.
  • 8Kim TY,Kim WB,Kim ES,et al.Serum thyroglobulin levels at the time of 131Ⅰ remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with well-differentiated thyroid carcinoma.J Clin Endocrinol Metab,2005,90:1440-1445.
  • 9Heemstra KA,Liu YY,Stokkel M,et al.Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.Clin Endocrinol (Oxf),2007,66:58-64.
  • 10Cooper DS,Doherty GM,Haagen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancr:the American Thyroid Association Guidelines Taskforce.Thyroid,2006,16:109-142.

共引文献46

同被引文献315

引证文献44

二级引证文献2141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部